Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06172660 · ClinicalTrials.gov registry record
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
A clinical trial of RSV Infection, sponsored by Yale University.
- Recruiting
- Registry status
- 3,750
- Enrollment target
- 1
- Study location
NCT06172660 is a study of RSV Infection that is actively recruiting participants, run by Yale University. The registered enrollment target is 3,750 participants, above the 278-participant average among 8 other RSV Infection trials with a reported enrollment target (1249% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06172660, a study of RSV Infection, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- 3,750 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to continue evaluating how well the RSV vaccines work as they are currently being used in routine clinical practice. Some of the questions that the investigators hope to answer with this study are: 1) What is the overall effectiveness of these vaccines? 2) How long does immunity last? 3) How effective are the vaccines against new strains? 3) Does the vaccine's effectiveness vary by age?
Conditions Studied
Interventions
- DRUG Nirsevimab
Study Locations (1)
Connecticut
- Yale Child Health Research Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,750 participants |
| Start Date | 2024-10-28 |
| Est. Completion | 2028-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06172660
The ClinicalTrials.gov registry entry for NCT06172660 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,750 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 278-participant average among 8 other RSV Infection trials with a reported enrollment target (1249% higher). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with RSV Infection appearing as the primary indexed condition, and to 1 intervention - of which Nirsevimab is the first listed.
NCT06172660 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT06172660 about?
NCT06172660 is a clinical study titled "Real-World Effectiveness of Perinatal RSV Immunoprophylaxis". The purpose of this study is to continue evaluating how well the RSV vaccines work as they are currently being used in routine clinical practice. Some of the questions that the investigators hope to answer with this study are: 1) What is the overall effectiveness of these vaccines? 2) How long does ...
What is the current status of trial NCT06172660?
This trial is currently recruiting. The enrollment target is 3,750 participants. The study started on 2024-10-28. Estimated completion is 2028-12-30.
What conditions does trial NCT06172660 study?
This clinical trial studies the following conditions: RSV Infection.
What interventions are being tested in trial NCT06172660?
The interventions under investigation include: Nirsevimab (DRUG).
Who is sponsoring clinical trial NCT06172660?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06172660 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for RSV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
RECRUITING · Phase 1
-
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
RECRUITING · Phase 3
-
SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies
ACTIVE NOT RECRUITING
-
Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)
COMPLETED · Phase 3
-
A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants
COMPLETED · Phase 1
-
A Study of EDP-323 in Healthy Subjects
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.